Compile Data Set for Download or QSAR
Report error Found 87 Enz. Inhib. hit(s) with all data for entry = 2132
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355665(US9815819, 30 | 1-(2-{(1R,3S,5S)-3-[(1R,2S)-2-(2-C...)
Affinity DataIC50: 22nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355637(US9815819, 2 | (1R,3S,5R)-2-[2-(3-Acetyl-indazol-1...)
Affinity DataIC50: 29nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355683(US9815819, 48 | 1-{2-[(1R,3S,5R)-3-((1R,2R)-2- Flu...)
Affinity DataIC50: 30nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355700(US9815819, 65 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 30nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355654(US9815819, 19 | 5-Ethyl-1-{2-oxo-2-[(1R,3S,5R)-3- ...)
Affinity DataIC50: 31nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355681(US9815819, 46 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 32nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355702(US9815819, 67 | 1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- ...)
Affinity DataIC50: 35nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355685(US9815819, 50 | US9815819, 52 | US9815819, 53 | 1-...)
Affinity DataIC50: 36nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355709(US9815819, 74 | US9815819, 75 | US9815819, 76 | US...)
Affinity DataIC50: 36nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355703(US9815819, 68 | 1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- ...)
Affinity DataIC50: 37nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355694(US9815819, 59 | (2S,4R)-1-[2-(3-Acetyl-indazol-1- ...)
Affinity DataIC50: 37nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355666(US9815819, 31 | (1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo...)
Affinity DataIC50: 37nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355693(US9815819, 58 | 1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2-C...)
Affinity DataIC50: 39nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355645(US9815819, 10 | (2S,3S,4S)-1-[2-(3-Acetyl-indazol-...)
Affinity DataIC50: 40nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355701(US9815819, 66 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 44nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355653(US9815819, 18 | 1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)-...)
Affinity DataIC50: 44nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355708(US9815819, 73 | 1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- ...)
Affinity DataIC50: 45nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355722(US9815819, 87 | 3-Acetyl-1-(2-{(1R,3S,5R)-3-[(1R,2...)
Affinity DataIC50: 46nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355674(US9815819, 39 | 1-{2-[(1R,3S,5R)-3-((1R,2R)-2-fluo...)
Affinity DataIC50: 48nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355661(US9815819, 26 | 5-Fluoro-1-{2-[(1R,3S,5R)-3- ((1R,...)
Affinity DataIC50: 60nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355647(US9815819, 12 | 1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)-...)
Affinity DataIC50: 60nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355698(US9815819, 63 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 64nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355644(US9815819, 9 | 1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- ...)
Affinity DataIC50: 65nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355679(US9815819, 44 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 66nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355706(US9815819, 71 | 1-(2-{(2S,4R)-4-Fluoro-2-[(1R,2S)-...)
Affinity DataIC50: 90nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355640(US9815819, 5 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo...)
Affinity DataIC50: 106nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355691(US9815819, 56 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 109nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355660(US9815819, 25 | 5,6-Difluoro-1-{2-[(1R,3S,5R)-3- (...)
Affinity DataIC50: 110nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355669(US9815819, 34 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazol...)
Affinity DataIC50: 112nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355713(US9815819, 78 | 1-{2-Oxo-2-[(1R,3S,5R)-3-(3- pheny...)
Affinity DataIC50: 114nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355650(US9815819, 15 | 5-Methyl-1-{2-oxo-2-[(1R,3S,5R)-3-...)
Affinity DataIC50: 115nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355652(US9815819, 17 | 1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)-...)
Affinity DataIC50: 117nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355649(US9815819, 14 | 1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)-...)
Affinity DataIC50: 118nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355662(US9815819, 27 | 5-Chloro-1-{2-[(1R,3S,5R)-3- ((1R,...)
Affinity DataIC50: 119nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355664(US9815819, 29 | (1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo...)
Affinity DataIC50: 119nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355643(US9815819, 8 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo...)
Affinity DataIC50: 123nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355705(US9815819, 70 | 1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- ...)
Affinity DataIC50: 125nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355697(US9815819, 62 | (1R,2S,5S)-3-[2-(3-Acetyl-indazol-...)
Affinity DataIC50: 131nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355675(US9815819, 40 | 1-(2-{(2S,4R)-4-Fluoro-2-[(1R,2S)-...)
Affinity DataIC50: 142nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355638(US9815819, 3 | (1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo...)
Affinity DataIC50: 147nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355663(US9815819, 28 | (1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo...)
Affinity DataIC50: 172nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355648(US9815819, 13 | 1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)-...)
Affinity DataIC50: 172nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355678(US9815819, 43 | 1-{2-[(1R,3S,5R)-3-((1R,2R)-2- Flu...)
Affinity DataIC50: 214nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355689(US9815819, 54 | (1R,3S,5R)-2-[2-(3-Acetyl-pyrazolo...)
Affinity DataIC50: 225nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355646(US9815819, 11 | (1R,3S,5R)-2-[2-(3-Acetyl-5,6- dim...)
Affinity DataIC50: 226nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355717(US9815819, 82 | 1-{2-Oxo-2-[(1R,3S,5R)-3-(3- pheny...)
Affinity DataIC50: 230nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355695(US9815819, 60 | (2S,4R)-1-[2-(3-Acetyl-indazol-1- ...)
Affinity DataIC50: 294nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355707(US9815819, 72 | 1-(2-{(2S,4R)-2-[(1R,2S)-2-(4- Chl...)
Affinity DataIC50: 309nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355667(US9815819, 32)
Affinity DataIC50: 326nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM355685(US9815819, 50 | US9815819, 52 | US9815819, 53 | 1-...)
Affinity DataIC50: 367nMAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2019
Entry Details
US Patent

Displayed 1 to 50 (of 87 total ) | Next | Last >>
Jump to: